EXEL News and Press, Exelixis Inc. From 05/01/23

Urges Shareholders to Vote " FOR " All of Exelixis’ 11 Recommended Director Nominees on the GOLD Proxy Card Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today announced that it has filed its definitive proxy materials with the Securities and Exchange Co...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2023 financial results will be released on Tuesday, May 9, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...

2023-04-22 06:55:00 ET One common misconception about the stock market is that you need a large sum of money to begin investing. But with a little patience, even a $20 investment in the right stocks can help you earn a handsome return. A small amount of money invested in growth stocks in va...

2023-04-13 17:16:58 ET Exelixis ( NASDAQ: EXEL ) supports two of investor Farallon's board nominees even as the investor last week said it planned to pursue a proxy fight with the biotech firm. Exelixis  ( EXEL ) said it's recommending Tomas Heyman, current CEO of ...

2023-04-10 08:26:10 ET Summary GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. Bristol-Myers Squibb's total debt was about $40.8 billion at the end of 2022, down $4.78 billion from the previous year, thanks to the successful integration of Celgene...

2023-04-10 05:43:55 ET Summary I found the pundits’ reaction to the March Jobs numbers biased to the negative. Similarly, many commentators are saying that the CPI numbers will be too high. Many have written with conviction that inflation is "sticky" yet the recession is ju...

2023-04-05 21:03:00 ET Update 9pm : Adds Exelixis comment. Exelixis ( NASDAQ: EXEL ) will face a proxy battle with hedge fund Farallon Capital, who last Monday announced it nominated three individuals for the biotech firm. Exelixis ticked up 1% in premarket trading. ...

2023-04-05 19:46:05 ET Exelixis ( NASDAQ: EXEL ) said it is focused on maximizing the potential of its cabozantinib franchise and advancing its pipeline in a direct rebuke to a letter made from Farallon Capital Wednesday morning. The biotech's management said that the comp...

Responds to Letter from Farallon Capital Management Exelixis, Inc. (Nasdaq: EXEL) (the “Company”) today issued the following statement in response to the letter issued by Farallon Capital Management, L.L.C. (“Farallon”): Successfully Executing Strategy ...

Believes the Company Must Focus R&D Efforts and Spending, Communicate a Coherent Strategy and Return Excess Capital to Shareholders in Order to Reverse Exelixis’ Track Record of Underperformance Intends to Nominate Three Accomplished, Independent Director Candidates Who Will Br...